Codagenix, Serum to start UK trials of nasal Covid vaccine in January
The companies said 48 volunteers will be enrolled at three dose levels and expect to begin dosing the trial participants in the first week of January
 "Codagenix, Serum to start UK trials of nasal Covid vaccine in January")
premium
Codagenix Inc and India's Serum Institute said on Monday they have received regulatory approval in the United Kingdom to begin an early-stage trial of their single-dose, intranasal Covid-19 vaccine.
The companies said 48 volunteers will be enrolled at three dose levels and expect to begin dosing the trial participants in the first week of January.
UK's Medicines and Healthcare Products Regulatory Agency (MHRA) approved the trial for the vaccine, COVI-VAC, after positive safety data in animal studies.The vaccine candidate uses Codagenix's Synthetic Attenuated Virus Engineering (SAVE) platform, which works by re-coding genes of viruses into safe and stable vaccines.
COVI-VAC will not need a needle and syringe or ultra-cold storage, the companies said, potentially addressing logistical issues likely faced by other vaccine-makers.
Serum Institute of India, the world's largest vaccine producer by volume, has also partnered with British drugmaker AstraZeneca to conduct trials of its vaccine in India and produce the vaccine candidate if it secures approval.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%